Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.395
-0.085 (-5.74%)
At close: Aug 14, 2026, 4:00 PM EDT
1.380
-0.015 (-1.08%)
After-hours: Aug 14, 2026, 7:55 PM EDT
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,876,555
Market Cap
6.00M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2024 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Sep 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Dec 31, 2021 | 3 | 0 | - | 3 | 0 |
| Mar 31, 2021 | 3 | - | - | 2 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| CollPlant Biotechnologies | 39 |
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| Cardio Diagnostics Holdings | 17 |
| NuCana | 12 |
| Purple Biotech | 10 |
| Dermata Therapeutics | 9 |
ACXP News
- 21 hours ago - Acurx Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 21 hours ago - Acurx Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 21 hours ago - Acurx Pharmaceuticals Earnings release: Q2 2026 - Filings
- 22 hours ago - Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - PRNewsWire
- 2 days ago - Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics - PRNewsWire
- 4 days ago - Acurx partners with Leiden University Medical Center to develop its antibiotics - TheFly
- 4 days ago - Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics - PRNewsWire
- 11 days ago - Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program - TheFly